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Abstract: Alpha7 nicotinic acetylcholine receptor (α7 nAChR) is an important part of the 
cholinergic nerve system in the brain. Moreover, it is associated with a cholinergic   
anti-inflammatory pathway in the termination of the parasympathetic nervous system. 
Antagonists of α7 nAChR are a wide group represented by conotoxin and bungarotoxin. 
Even Alzheimer’s disease drug memantine acting as an antagonist in its side pathway 
belongs in this group. Agonists of α7 nAChR are suitable for treatment of multiple 
cognitive dysfunctions such as Alzheimer’s disease or schizophrenia. Inflammation or even 
sepsis can be ameliorated by the agonistic acting compounds. Preparations RG3487, 
SEN34625/WYE-103914, SEN12333, ABT-107, Clozapine, GTS-21, CNI-1493, and   
AR-R17779 are representative examples of the novel compounds with affinity toward the 
α7 nAChR. Pharmacological, toxicological, and medicinal significance of α7 nAChR are 
discussed throughout this paper.  
Keywords:  inflammation; cholinergic anti-inflammatory pathway; schizophrenia; 
Alzheimer’s disease; cognitive disorder; agonist; antagonist 
 
1. Introduction 
Pharmacological neuromodulation has become one of the suitable tools for influencing the whole 
system of the human body. However, the interest in this is undermined by the fact that drugs 
specifically implicated in neuromodulation will be more potent than the ones influencing the periphery 
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due to their effect amplification. Nevertheless, the current attention is aimed at the treatment of 
illnesses associated with neuropathology e.g., schizophrenia, Alzheimer’s and Parkinson disease.  
Because the nerve system is connected with many processes, the neuromodulation can be used for 
alteration of, e.g., the immune system or to slow down degenerating processes. This review is focused 
on α7 nicotinic acetylcholine receptor as a pharmacological target. The receptor is well known for its 
role in the central nervous system but only recently a connection of the immune system and 
parasympathetic nervous system was recognized. Future perspectives are introduced here.  
2. Acetylcholine as Neurotransmitter 
The cholinergic system is one of the excitatory pathways participating in the parasympathicus, 
sympathicus, and the central nervous system using acetylcholine as a neurotransmitter [1]. Loewi was 
the first investigator that proposed the physiological importance of the simple compound acetylcholine 
in the 1920s [2]. Acetylcholine and acetylcholine receptors are known to be present on many cell types 
including endothelial cells and cells of the immune system [3].  
Acetylcholine is synthesized from two precursors: acetyl coenzyme A and choline using enzyme 
choline O-acetyltransferase (ChAT; EC 2.3.1.6). ChAT with higher activity is localized in cytosol near 
neurosynapses as a soluble molecule. However, ChAT can be also found as a membrane bound 
structure [4]. The localization of ChAT in neurons by immunohistopathology is a basic tool for 
distinguishing between cholinergic and adrenergic nerve system [5]. Acetylcholine established in 
neurons is antiported by protons into vesicles using vesicular acetylcholine transporter (VAChT). 
Interaction of vesicles with the neurosynapse membrane is possible only if change in calcium level 
inside the cell takes place. The process is assisted by vesicle-associated membrane proteins (VAMP). 
The absorbed calcium molecules interact with C2A and C2B subunits of synaptotagmin [6]. 
Synaptoprevin in the presence of calcium forms a complex with synaptosomal-associated protein 25 
(SNAP-25) which is weakly bound on the inner membrane of synapse [7]. Subsequently, syntaxin, 
another molecule on the inner membrane undergoes interaction with the complex resulting in the final 
formation of a complex soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptors 
(SNARE) necessary for acetylcholine vesicles fusion with membrane [8]. Acetylcholine is released by 
fusion of the vesicles and cell membranes and interacts with acetylcholine receptors (AChR).  
Acetylcholine is a chemically stable compound that can persist for a long time after spreading into 
the neurosynaptic cleft and spontaneous elimination is slow due to the quaternary ammonium atom in 
the choline moiety. For this reason, enzyme acetylcholinesterase (AChE) is present in the neurosynaptic 
cleft to quickly terminate the signal. AChE splits acetylcholine into acetic acid and choline [9] while 
choline is transported from the neurosynaptic cleft using high-affinity choline transporter (ChT) back 
to the cytosol, acetic acid is further decomposed [10]. The complete scheme of cholinergic 
neurotransmission is depicted in Figure 1. 
In addition to AChRs and AChE, other proteins related to vesicles fusion are also targets of 
numerous toxins e.g., butulotoxins. These endopeptidases are produced by bacteria Clostridium 
botulinum and less commonly by C. baratii and C. butyricum [11,12]. Butulotoxin is a dimer 
composed of 100 kDa heavy chain and 50 kDa light chain with Zn
II+ endopeptidase activity [13]. 
There are seven basic isoforms of butulotoxine (A, B, C, D, E, F, and G) with different substrate Int. J. Mol. Sci. 2012, 13                 
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selectivity [14]. A, C and E split SNAP 25 while B, D, F and G split synaptobrevin. The last type C 
splits syntaxin.  
Figure 1. Overview of cholinergic neurotransmission: ACh—acetylcholine; Ac—acetate; 
AChE—acetylcholinesterase; AChR—acetylcholine receptor; ChAT—choline   
O-acetyltransferase; ChT—high-affinity choline transporter; VAChT—vesicular 
acetylcholine transporter, 1—axonal termination of neuron; 2—dendrite of neuron or other 
target cell. 
 
3. Acetylcholine Receptors  
Two types of AChRs are known: muscarinic (mAChR) and nicotinic (nAChR). Names are derived 
from responds to interactions with secondary metabolites recognized as selective agonists. Muscarine 
is a fungal natural parasympathomimetic from the fly amanita (Amanita muscaria). The mAChRs can 
be found in the central as well as peripheral nervous system. In an extensive level it is inherent in the 
neuromuscular junction and endocrine glands. In comparison with nAChR, mAChR are coupled with 
G proteins [15]. In compliance with the former approach, mAChRs were divided into two separate 
groups: the first was stimulatory, connected with the activity of phospholipase C, the second type is 
inhibitory based on the suppression of adenylate cyclase activity [16]. Five types of mAChRs are 
currently known: M1, M2, M3, M4 and M5 [17]. The types M1, M3, and M5 are connected with the 
accumulation of intracellular calcium and activation of phospholipases. The preference junction of the 
M1, M3 and M5 is toward Gq and G11 [18,19]. The last subtypes M2 and M4 inhibit adenylate cyclase 
via Gi or Gz [20,21]. Atropine is a known secondary metabolite from solanum plants (Solanaceae) and 
is probably the best-known antagonist of acetylcholine on mAChR. Atropine is widely used for the 
treatment of bradycardia and asystole [22] and can also protect mAChR from overstimulation when 
AChE becomes inhibited e.g., by nerve agents [23]. Scopolamine is another antagonst of M1 receptors 
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used in ophthalmology and for suppression of nausea [24]. Modulation of mAChR can be also suitable 
for the treatment of psychotic disorders [25]. Stimulation of M1 and M4 can suppress effect of 
amphetamines [26] and stimulation of M1 is perspective in the development of drugs for schizophrenia 
treatment [27]. Combination of M1 agonists and AChE inhibitors promotes REM sleep [28]. 
Nicotinic acetylcholine receptors (nAChR) are named after natural agonist nicotine, a secondary 
metabolite from a common tobacco plant (Nicotiana tabacum, Solanaceae). Nicotine alone is used to 
wean patients from smoking and in combination with other ingredients of cigarette smoke reduces 
schizophrenia manifestations [29,30]. However, it is unclear whether nicotine influences cognitive 
functions during schizophrenia by nAChR agonism or if it is implicated in monoamine oxidase activity 
modulation [31]. Currently, clinical trials are conducted to confirm nicotine’s benefits to patients with 
Parkinson’s disease, schizphrenia, sarcoidosis, and as pain relief [32]. It is widely accepted that 
nAChRs are present in both central and peripheral sections of the nerve system and neuromuscular 
junctions. In addition, evidence suggests nicotine also participates in the nerve-immune system 
junction [33] as introduced later.  
In mammals, analysis of cDNA proved existence of 17 homologues of nAChR’s subunits divided 
into five subtypes: α1-10, β1-4, γ, δ, ε [34]. Except of the avian subtype α8, all subtypes can be found 
in mammals [35]. One nAChR molecule is composed from five subunits formed in radial symmetry 
with central pore. Each subunit includes four transmembrane α helixes, large intracellular domain 
composed from one α helix and extracellular part with affinity to acetylcholine and other agonists [36]. 
Acetylcholine is bound in a cavity formed by the disulfide bridge from the two cysteine residues. From 
the known subtypes, the cavity is formed by α1, α2, α3, α4, α6, α7 and α8 subtypes only. The other 
subtypes, α1, β2, β4, δ, γ and ε, may stabilize cavity from the outside [37]. Homopentamer α7 as well 
as some other receptors have the affinity not only to acetylcholine but also to choline [38]. The 
individual subtypes can be combined one to each other with different stechiometry. The (α7)5, (α4)2(β2)3, 
(α4)3(β2)2 a (α4)2(β2)2α5 nAChR are the most common [39,40]. Mechanism of the nAChR’s function 
is the same for all receptors regardless to presence of different subtypes. It forms an ion channel every 
time. However, the main difference is in which ions are allowed to flow through the receptor. The 
presence of polar regions and/or subtype α3 will allow selective flow of Na
I+ and K
I+. On the other 
hand, non-polar residua and a high level of glutamic acid typical for the α7 nAChR homopentamer, 
enhance specificity to Ca
II+ [41]. 
nAChRs are influenced by several toxins and pharmacologically applicable compounds e.g., α 
bungarotoxin from the Taiwan krait Bungarus multicinctus. It is a strong antagonist of nAChRs with 
partial selectivity to α7 nAChR [42]. nAChRs are considered to be a strong antagonist on 
succinylcholine (suxamethonium), they are used for recovery from near fatal hyperthermia [43] and 
neuromuscular junction paralysis in anesthesia [44]. Since succinylcholine is converted by plasmatic 
butyrylcholinesterase, butyrylcholinesterase dysfunctional patients are extremely sensitive to 
succinylcholine and recovery from its application lasts longer when compared to individuals with fully 
active butyrylcholinesterase [45]. 
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4. α7 Nicotinic Acetylcholine Receptor in Brain 
The α7 nAChR is implicated in cognitive functions of the central nervous system. Modulation of α7 
nAChR is considered to be perspective for the treatment of cognitive disorders such as Alzheimer’s 
disease or schizophrenia. Agonists of α7 nAChR are able to penetrate through the blood brain barrier. 
They are objects of pharmacologists’ interest as they are suitable for cognitive function amelioration in 
patients suffering from Alzheimer’s disease and schizophrenia [46]. Moreover, amyloid β released in 
Alzheimer’s disease patients also extensively binds to the brain α7 nAChR and prevents its natural 
function [47]. As acetylcholine level is limited in Alzheimer’s disease damaged brain agonizing α7 
nAChR is considered as a promising way to enhance cognitive functions [48]. Feher et al. investigated 
the link between α7 nAChR and some types of dementia [49]. They recognized significantly elevated  
2 bp deletion in α7 nAChR subunit gene in individuals suffering from Alzheimer’s disease, dementia 
with Lewy bodies, and Pick’s disease. Moreover, actual α7 nAChR is over-expressed in patients with 
Alzheimer’s disease [50]. These findings should be extensively researched and molecular mechanism 
of α7 nAChR in neurodementias has to be better understood before any conclusions can be made.  
Experimental application of α7 nAChR agonists can be beneficial in schizophrenia treatment e.g., 
Tregellas  et al. successfully tested 3-(2,4-dimethoxybenzylidene) anabaseine as a α7 nAChR   
agonist [51]. It is vital that cholinergic nerves can modulate release of dopamine and glutamate. 
Livingston  et al. proved that α7 nAChR might be stimulated by choline. Moreover, they tested 
compound PNU-120596 (see later) and proved that it elicits dopamine release in the rat prefrontal 
cortex [52]. Effectiveness of α7 nAChRs agonists is intriguing for schizophrenia treatment. Drugs for 
schizophrenia Clozapine and 3-(2,4-dimethoxybenzylidene) anabaseine can be used as an example of 
drugs implicated in α7 nAChR agonism [53]. Special animal models have been introduced in order to 
investigate the α7 nAChR modulation by chemical compounds for, e.g., Alzeheimer’s disease and 
other disorders [54–56].  
5. Cholinergic Anti-Inflammatory Pathway 
Cholinergic anti-inflammatory pathway is a link between parasympathetic and innate immune system. 
Tracey and co-workers firstly described it as they recognized nervus vagus in immunomodulation and 
called it inflammatory reflex [57]. Scheme of cholinergic anti-inflammatory pathway is depicted as 
Figure 2. Macrophages are able to produce pro-inflammatory cytokines e.g., tumor necrosis factor α 
(TNFα) and expression of high-mobility group protein 1 (HMG 1) with intracellular as well as 
extracellular signalization function. Regarding cholinergic anti-inflammatory pathway, principal 
parasympathetic terminations in the blood system are able to release acetylcholine that interacts with 
α7 nAChR on macrophages surface. Macrophage-assisted inflammation is stopped after the receptor 
stimulation. During inflammation the α7 nAChR action is associated with calcium influx and stop of 
nuclear factor B (NF B) stimulation [58–60]. 
Inflammatory processes can be deteriorating without being properly controlled. Septic shock can be 
mentioned as an example. It is a life-threatening event with high expected mortality rate [61]. Another 
deteriorating action of immune system represented by macrophages is atherosclerosis [62]. 
Macrophages are also a target in HIV pathology as virus can proliferate within and the pathology is Int. J. Mol. Sci. 2012, 13                 
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also involved in macrophage mediated bystander T lymphocytes apoptosis [63]. Stimulation of the 
cholinergic anti-inflammatory pathway is believed to be a neuro-immunomodulatory action with fast 
and reliable calming of the innate immune system [64]. The cholinergic anti-inflammatory pathway 
was proven to be effective in sepsis treatment [65], in ischemia (myocardial ischemia reperfusion 
injury) [66], and rheumatoid arthritis [67]. 
Figure 2. Scheme of cholinergic anti-inflammatory pathway: ACh—acetylcholine; TNF 
α—tumor necrosis factor α; HMG 1—high-mobility group protein 1. 
 
6. Antagonists of α7 nAChR 
Agonists and antagonists of α7 nAChR are a wide group of heterogeneous compounds. Antagonists 
of α7 nAChR have lower practical impact in comparison with agonists. Several natural toxins can be 
used as examples of compounds antagonizing acetylcholine on α7 nAChR [32]. Moreover, some drugs 
are potent to antagonize α7 nAChR as a side effect of their main pharmacological effect. Two groups 
of proteins’ respective peptides are the best-known antagonists of α7 nAChR. Conotoxins are a group 
of cysteine-rich peptides from cone snails (Conus sp.) possessing various ion channel blocking. The α 
conotoxins selectively target the nAChR [68]. They contain two-loop frameworks and are selective to 
the acetylcholine binding site [69]. α connotoxins from cone snail Conus consors abbreviated as CnIA 
with sequency GRCCCHPACGKYYSC and amidated C terminus are selective and reversible 
antagonists of α7 nAChR [70]. However, the other α conotoxins such as α conotoxin PnIA are also 
antagonists of α7 nAChR with low median inhibitory concentration: 14 nM [71]. Conotoxins are 
potent inhibitors of nAChR when considered the median inhibitory concentration for the individual 
toxins. The strongest inhibitors possess median inhibitory concentration in nanomolar levels [72]. Due 
to their size and physical properties, conotoxins cannot simply cross the blood brain barrier. Thereby 
their action is preferably in the peripheral nervous system [73]. On the other hand, distribution to the 
central nervous system is not restricted and central action of conotoxins can be also recognized in 
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some cases [74]. Though the conotoxins are not utilized for pharmacology purposes, they were found 
to be suitable for distinguishing between individual types of nAChR [75]. 
α Bungarotoxin is another specific antagonist of α7 nAChR. It is venom from Taiwanese krait 
Bungarus multicinctus. Beside α7 nAChR, α bungarotoxin can also bind on to GABA β3 subunit [76]. 
The isolation of α Bungarotoxin and understanding mechanism of action has been extensively 
investigated from 1960s [77,78]. α Bungarotoxin binds irreversibly to the nAChR and the complex 
bungarotoxin—nAChR is immunogenic, which may result in production of autoimmune antibodies. 
For this reason, α bungarotoxin is a suitable experimental model for myasthenia gravis [79]. 
Memantine (3,5-Dimethyl-tricyclo[3.3.1.13,7]decan-1-amine hydrochloride) and methyllycaconitine 
are low molecular weight antagonists of α7 nAChR. Memantine (Figure 3) is an approved drug for 
treatment of Alzheimer’s disease acting as a strong NMDA receptor antagonist. Beside the action on 
NMDA receptors, memantine was proved to be a α7 nAChR antagonist with median inhibitory 
concentration 0.34 µM [80]. Although Aracava et al. considered antagonism of memantine on α7 
nAChR as a negative phenomenon in Alzheimer’s disease treatment [80], the antagonism is considered 
to be beneficial in Alzheimer’s disease treatment according to other scientists [81]. However, the 
significance of the antagonism should be elucidated and antagonism suitability for Alzheimer’s disease 
treatment is not a common view; more trials are needed [82]. Methyllycaconitine is a 683 Da 
weighting secondary metabolite from Consolida genus. It is an antagonist of nAChR with the highest 
affinity to α7 subtype [83,84]. However, there still remains one group of nAChR antagonists that were 
not mentioned in the previous text: pyridinium oximes and bispyridinium oximes. These compounds 
are used for antidotal treatment after exposure to organophosphorous inhibitors of AChE [85]. It was 
proved that these compounds can bind like acetylcholine due to the quarternary ammonium atom and 
interact with AChE and with AChR [86,87]. Biological effects HI-6 (asoxime; Figure 3) are 
considered to be associated with α7 nAChR; unfortunately the plausible proof is still missing [88,89]. 
The antagonists of α7 nAChR are summarized in Table 1. 
Figure 3. Structures of memantine and HI-6. 
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Table 1. Overview of selected α7 nAChR antagonists. 
Name Structure  Source  Use  Reference
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683 Da alkaloid 
CAS: 21019-30-7 
Consolida flowers 
not used in therapy, natural 
toxin 
[83–84] 
7. Agonists of α7 nAChR 
α7 nAChR agonists become a group of extensively investigated compounds. As was mentioned 
above, agonists are perspective for the treatment of cognitive dementia, schizophrenia, inflammation 
and sepsis regarding to the physiological importance of α7 nAChR. However, structural requirements 
for these drugs are quite different. Drugs suitable for schizophrenia and dementia treatments have to be 
able to penetrate the blood brain barrier. On the other hand, the cholinergic anti-inflammatory pathway 
can be also be controlled by compounds that are not distributed into the central nervous system. The 
blood brain barrier penetrating compounds are typically small lipophilic molecules with no charged 
atom [90,91] and/or recognizable by specific carriers [92]. Piperidyl or azabicyclooctane derivatives 
are the most common derivatives. 
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Figure 4. Structures of α7 nAChR agonists acting in the central nervous system. 
 
Selected pharmacologically relevant agonists of α7 nAChR are depicted in Figure 4. Wallace et al. 
prepared compound RG3487, N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-3-carboxamide 
hydrochloride recognized as a human α7 nAChR agonist with high affinity represented by equilibrium 
constant 6 nM and median effective concentration 0.8 µM [93]. RG3487 was also proved as a potent 
antagonist of serotonin receptor with median inhibitory constant 2.8–33 nM. The authors proved the 
significant effect of the compound on rodents’ cognitive functions and discussed perspectives for 
Alzheimer’s disease symptomatic treatment. Moreover, it was proven to reverse phencyclidine-induced Int. J. Mol. Sci. 2012, 13                 
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impairments in a rodent model. Another agonist of α7 nAChR for cognitive disorders treatment was 
introduced by Chiron et al. [94]. They introduced 1-[6-(4-fluorophenyl) pyridin-3-yl]-3-(4-piperidin-1-
ylbutyl) urea, abbreviated as SEN34625/WYE-103914, that is a strong agonist of α7 nAChR as the 
median effective concentration was 70 nM. SEN34625/WYE-103914 is the more effective analogue of 
previously prepared compound SEN12333 (5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-
amide) promising for Alzheimer’s disease and schizophrenia treatment with median effective 
concentration to α7 nAChR 12 µM [95]. The compound crosses the blood brain barrier well and can be 
administered orally. ABT-107 is also an agonist of α7 nAChR structurally different to SEN 
compounds [96]. Median effective concentration for ABT-107 was 50–90 nM for rat oocytes. 
According to the author’s report, ABT-107 was also found to be effective in protecting rat cortical 
cultures from glutamate-induced toxicity. In the text above, clozapine (8-chloro-11-(4-
methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine) and 3-(2,4-dimethoxybenzylidene) anabaseine 
were mentioned as drugs acting as a α7 nAChR agonists [51,53]. However, clozapine is a commercial 
antipsychotic for schizophrenia [97] and interaction with α7 nAChR is not the main pharmacological 
pathway. It is sold under different trade names e.g., Azaleptin, Clozaril, FazaClo, Leonex and others. 
Besides those mentioned above, some other compounds are in clinical trials and are at the center of 
extensive scientific interest. PNU-120596 (1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-
yl)urea) is a potent allosteric modulator [98] with good potential to act as a neuroprotective agent 
enhancing cognition ability [99]. Compound TC-5214 (S-(+)-mecamylamine) is nAChR antagonist 
with low selectivity toward individual isotypes [100]. Presently, the TC-5214 preparation is evaluated 
for its palliative and antidepressant effect. Promising compounds acting as a α7 nAChR selective 
agonists seem to be also AZD0328 and TC-5619, both containing azabicyclooctane group. They are 
expected to be useful to treating multiple cognitive dysfunctions and schizophrenia [101,102]. It is 
noteworthy that product of acetylcholine hydrolysis, choline, is an agonist of α7 nAChR, too [103].  
Compounds eliciting cholinergic anti-inflammatory pathway are another group of promising drugs. 
Immunology principle of the cholinergic anti-inflammatory pathway was extensively reviewed 
recently [64,104]. Pharmacological stimulation of the pathway seems to be suitable for treatment of 
multiple diseases associated with over stimulation of immune system such as autoimmune disorders, 
sepsis, acute pancreatitis etc. [105,106]. Presently, there is no clinically approved drug primary 
targeted on cholinergic anti-inflammatory pathway. However, certain novel compounds seem to be 
promising for the pertinent clinical trials. An example is [3-(2,4-dimethoxybenzylidene) anabaseine] 
abbreviated as GTS-21 or DMXB-A in some sources. It is a compound found in Pacific nemertine 
Paranemertes peregrina and currently tested for treatment of Alzheimer’s disease and cognitive 
deficits associated with schizophrenia [107]. It is able to attenuate TNF α as well as other   
pro-inflammatory cytokines production. GTS-21 (Figure 5) was able to improve survival rate of 
BALB/c mice suffered from endotoxemia when applied in dose 4 mg/kg [108]. As proved on a 
C57BL6 mouse model, the compound is also suitable for prevention of inflammatory injury induced 
by mechanical ventilation [109]. In addition to the anti-inflammatory pathway, GTS-21 was assessed 
in a clinical trial and was proved to improve the cognitive functions of schizophrenic patients [110]. A 
tertravalent guanylhydrazone CNI-1493 (Figure 5) known also as semapimod (N,N’-bis[3,5-bis[N-
(diaminomethylideneamino)-C-methylcarbonimidoyl] phenyl] decanediamide tetrahydrochloride) is an 
agonist of α7 nAChR primary introduced as a selective pro-inflammatory cytokine inhibitor [111] Int. J. Mol. Sci. 2012, 13                 
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suitable for activation of cholinergic anti-inflammatory pathway [112]. In addition to this, it 
ameliorates amyloid β deposition and it is a perspective for treatment of cognitive deterioration in 
Alzheimer’s disease. It acts via suppression of inflammation with perspective to amend disease 
progression [113]. CNI-1493 was found to be effective for resolving of endotoxic shock in a rat model 
[114]. In a clinical trial, CNI-1493 was examined as a drug for the treatment of Crohn’s disease [115], 
a disease associated with inflammation. The investigators reported no plausible effect for CNI-1493 
single and 3 day dosing. However, cumulative dosing brings some positive effects to Crohn’s disease 
therapy. Anti-inflammatory properties were also found for a α7 nAChR agonist AR-R17779 ((2S)-
2’H-spiro[4-azabicyclo[2.2.2]octane-2,5’-[1,3]oxazolidin]-2’-one) which is reported to be suitable for 
amelioration of ileus in mice [116]. AR-R17779 (Figure 5) can also act in the central nervous system 
where it can ameliorate cognitive function [117]. Selected α7 nAChR antagonists are summarized in 
Table 2. 
Figure 5. Structures of α7 nAChR agonists with significant anti-inflammatory properties. 
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Table 2. Overview of selected α7 nAChR antagonists. 
Name Structure  Use  Reference
ABT-107 
5-(6-[(3R)-1-
azabicyclo[2.2.2]oct-3-
yloxy]pyridazin-3-yl)-1H-indole 
Treatment of Alzheimer’s disease and cognitive 
deficits associated with schizophrenia, under 
testing, not comercially available 
[96] 
SEN12333 
5-morpholin-4-yl-pentanoic acid 
(4-pyridin-3-yl-phenyl)-amide 
[95] 
TC-5619 
N-[(2S,3S)-2-(pyridin-3-
ylmethyl)-1-azabicyclo[2.2.2]oct-
3-yl]-1-benzofuran-2-
carboxamide 
[102] 
Clozapine 
8-chloro-11-(4-methylpiperazin-
1-yl)-5H-
dibenzo[b,e][1,4]diazepine 
Commercially available drug (trade names 
Azaleptin, Clozaril, FazaClo, Leonex and 
others), used as antipsychotics in paranoid 
disorders and schizophrenia 
[51,53] 
CNI-1493 
N,N’-bis[3,5-bis[N-
(diaminomethylideneamino)-C-
methylcarbonimidoyl]phenyl] 
decanediamide tetrahydrochloride
Inhibitor of inflammation and NO production, 
antagonist of α7 nAChR via cholinergic  
anti-inflammatory pahtway, known as a drug 
Semapimod, under clinical trials 
[112–115]
GTS-21 (or 
DMXB-A) 
3-[(3E)-3-[(2,4-
dimethoxyphenyl)methylidene]-
5,6-dihydro-4H-pyridin-2-yl] 
pyridine 
Treatment of Alzheimer’s disease and cognitive 
deficits associated with schizophrenia, 
experimental testing for  
anti-inflammatory potency, under  
clinical testing 
[107–110]
8. Conclusions  
Agonists and antagonists of α7 nAChR are pharmacologically relevant compounds suitable for 
treatments of multiple cognitive dysfunctions and/or inflammation associated diseases. Although drugs 
specifically targeted to α7 nAChR are not clinically approved, the recent investigations provided good 
preliminary results. In compliance with the known facts about novel compounds, increased clinical 
interest and clinical trials for the novel drugs can be expected.  
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